Abstract
Damaged DNA can lead to aneuploidy and/or chromosomal instability, which is believed to be major contributor to tumor progression. DNA damage in response to genotoxic and oncogenic stresses activate the tumor suppressor pathways initiating DNA damage response (DDR). One of the cellular fates in response to DDR is permanent growth arrest in mitotically active cells, including stem cells, leading to senescence. On the other hand, DDR reasons in adaptive changes in postmitotic cells. These cellular alterations happen through complex interactions and function to disrupt the existing cellular homeostasis. Significant metabolic changes occurred by the influence of the major tumor suppressor protein p53 and other related factors such as FOXO, AMPK, PARP, NF-κB and PGC-1 are discussed in the article. After a strong correlation established between the systemic DNA damage response to inhibit ongoing malignant transformation and metabolic syndrome characteristics, logical extrapolations for type 2 diabetes, cardiovascular disease, and aging are carried out. Finally, therapeutic evaluations are performed in the light of the novel pathophysiological data implying that “metabolic syndrome” is a real disease.
Keywords: Metabolic syndrome, senescence, insulin resistance, oxidative stress, p53, FOXO, PARP
Current Molecular Medicine
Title: Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Volume: 10 Issue: 3
Author(s): A. Erol
Affiliation:
Keywords: Metabolic syndrome, senescence, insulin resistance, oxidative stress, p53, FOXO, PARP
Abstract: Damaged DNA can lead to aneuploidy and/or chromosomal instability, which is believed to be major contributor to tumor progression. DNA damage in response to genotoxic and oncogenic stresses activate the tumor suppressor pathways initiating DNA damage response (DDR). One of the cellular fates in response to DDR is permanent growth arrest in mitotically active cells, including stem cells, leading to senescence. On the other hand, DDR reasons in adaptive changes in postmitotic cells. These cellular alterations happen through complex interactions and function to disrupt the existing cellular homeostasis. Significant metabolic changes occurred by the influence of the major tumor suppressor protein p53 and other related factors such as FOXO, AMPK, PARP, NF-κB and PGC-1 are discussed in the article. After a strong correlation established between the systemic DNA damage response to inhibit ongoing malignant transformation and metabolic syndrome characteristics, logical extrapolations for type 2 diabetes, cardiovascular disease, and aging are carried out. Finally, therapeutic evaluations are performed in the light of the novel pathophysiological data implying that “metabolic syndrome” is a real disease.
Export Options
About this article
Cite this article as:
Erol A., Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065282
DOI https://dx.doi.org/10.2174/156652410791065282 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: What's Behind the Sex Gap in Cardiovascular Mortality?)
Current Pharmaceutical Design Healthspan and Longevity in Mammals: A Family Game for Cellular Organelles?
Current Pharmaceutical Design Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Cardiopulmonary Interactions in Children with Heart Failure
Current Cardiology Reviews Mitochondria and Organismal Longevity
Current Genomics Sirolimus: A Novel Immunosuppressive Drug in Heart Transplantation
Recent Patents on Cardiovascular Drug Discovery Cardiac MRI in Infiltrative Disorders: A Concise Review
Current Cardiology Reviews Nano-antibiotics: A Therapeutic Future
Nanoscience & Nanotechnology-Asia Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Matrix Metalloproteinases: A Potential Therapeutic Target in Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Current Pharmaceutical Design Biomarkers of Oxidative Stress and Cataract. Novel Drug Delivery Therapeutic Strategies Targeting Telomere Reduction and the Expression of Telomerase Activity in the Lens Epithelial Cells with N-Acetylcarnosine Lubricant Eye Drops: Anti-Cataract which Helps to Prevent and Treat Cataracts in the Eyes of Dogs and other Animals
Current Drug Delivery Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Diabetic Cardiomyopathy and its Prevention by Metallothionein: Experimental Evidence, Possible Mechanisms and Clinical Implications
Current Medicinal Chemistry Mini Review: Recent Advances in the Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy